Company Overview and News

 
FY18 to FY20 estimated to be Tune Protect’s recovery years

2018-08-15 theedgemarkets
Tune Protect Group Bhd (Aug 14, 94.5 sen) Maintain buy with a higher target price of RM1.20: Compared with financial year 2017 (FY17), which saw Tune Protect Group Bhd’s core net profit suffered a 40% decline year-on-year arising from high motor claims liabilities, adverse effects of “opt-in” regulatory changes and higher marketing expenses, we believe that the FY18 to FY20 period will potentially be recovery years.
5230

 
Possible uptrend continuation for Tune Protect, says PublicInvest Research

2018-06-29 theedgemarkets
KUALA LUMPUR (June 29): PublicInvest Research said that after a week of congestion, Tune Protect Group Bhd’s price movement is picking up its prior uptrend.
5230

 
Tune Protect to leverage Laka insurtech expertise with stake buy

2018-06-11 theedgemarkets
Tune Protect Group Bhd (June 8, 84.5 sen) Maintain buy with a fair value (FV) of RM1.10: We maintain our “buy” call on Tune Protect Group Bhd with an unchanged FV of RM1.10 per share, pegging the stock at a financial year ending Dec 31, 2019 (FY19) price-to-book ratio of 1.4 times.
5230

 
Stock analysis

2018-05-29 thestar.com.my
TONG Herr’s first quarter earnings of RM16.5mil were in-line at 27% of full-year estimates, according to RHB Research.
5230

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...